Real World Evidence of Anifrolumab in Systemic Lupus Erythematosus: Investigator Initiated, Observational, Multicenter Study Evaluating Effectiveness and Safety of Anifrolumab in Active SLE Patients
Patients diagnosed with SLE according to classification criteria valid at diagnosis time (1997, 2012, 2019)
Written informed consent
Active disease for which the patient is a candidate for Anifrolumab treatment (including compassionate use)
Active disease for which the patient has started Anifrolumab treatment
You may not be if
Age \<18 years
Absence of patient consent
Clareo Health | Real World Evidence of Anifrolumab in Systemic Lupus Erythematosus: Investigator Initiated, Observational, Multicenter Study Evaluating Effectiveness and Safety of Anifrolumab in Active SLE Patients
